<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;L01F&quot;,&quot;href&quot;:&quot;atc/L01F.md&quot;},{&quot;label&quot;:&quot;tisotumab vedotin&quot;}]"></div>

# tisotumab vedotin

- **generic name:** tisotumab vedotin
- **ATC codes:** `L01FX23`
- **DrugBank:** [DB16732](https://go.drugbank.com/drugs/DB16732) · **PubChem:** not captured
- **groups:** approved, investigational

## About

Tisotumab vedotin is an antibody-drug conjugate used to treat cervical cancer. It is authorised in the European Union and also remains under investigation for other uses.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q108670929](https://www.wikidata.org/wiki/Q108670929) and the WHO ATC classification and the EMA medicines list; not checked by a person.</small>

## Molecular properties

> Molar masses support mass–molar conversion and metabolite stoichiometry. Sources: DrugBank (parent), reported values or identity-matched PubChem entries (metabolites).

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| monomethyl auristatin E | metabolite | 1250 | — | the paper | — | Gibiansky_2022 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-07 21:18 | 2:58 | 0/0/1 | 0/0/0 | 0/0/0 | 59,927/6,874 | ollama / qwen3.8:27b-mtp-q8_0 | 4 | 0/2 | 4/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss-120b (partly confirmed, agreement 0.933). Primary extraction retained.">cross-check: partial</span><br><sub>blocking: C5 dimensioned parameter(s) without a unit: Q66 — no SI value to build from</sub><br><sub>route_to: `human_review`</sub> | [Gibiansky_2022_reference](drugs/drug_tisotumab_vedotin/TisotumabVedotin_Gibiansky2022_reference.md) | — | parent + metabolite (no model) | 14 | Gibiansky L et al., Population pharmacokinetic analysis for…, CPT: pharmacometrics & syst… (2022) | [10.1002/psp4.12850](https://doi.org/10.1002/psp4.12850) |

<details class="legend">
<summary>Status and cross-check definitions</summary>
<table><thead><tr><th>Badge</th><th>Definition</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>Human-authored reference record or exemplar.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>Accepted extraction; applicable closed-form checks passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>Generated-model predictions agree with reported reference values; not human-verified.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>Replication accepted with unresolved advisory checks.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>Incomplete, inconsistent, or implausible extraction; values remain unverified.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>Model withheld because a core parameter uses a library default.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>Unaccepted record; displayed values remain unverified.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>Model generation pending or unavailable; not a validation verdict.</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>Review predates the current extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>All responding readers agree on all compared fields; fractions indicate agreeing/total readers.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>At least one non-structural discrepancy or incomplete reader agreement.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>At least one structural-parameter discrepancy; primary extraction retained pending review.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>Non-human or in-vitro evidence; parameters and simulations describe the stated experimental system.</td></tr></tbody></table>
<p><small><b>Status</b> reports validation and review outcomes; <b>cross-check</b> reports agreement between independent extractions. Agreement does not establish plausibility, model validity, or clinical applicability.</small></p>
</details>

## Coverage

- **PubMed hits:** 7 matched, 7 returned
- **screened:** 1  ·  **relevant:** 1
- **records:** 1  ·  extracted 0  ·  needs_review 1  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Passey_2023 | irrelevant | 2 | 0 | The paper reports exposure-response (safety/efficacy) relationships using PK parameters but does not report the quantitative population PK model parameters (CL, V, Q, etc.) for tisotumab vedotin, which are referenced as being in a separate report (Ref 25) or supplementary material not provided. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-07 21:16 UTC</sub>
